z-logo
Premium
A more sensitive detection of micrometastases of NSCLC in lymph nodes using the one‐step nucleic acid amplification (OSNA) method
Author(s) -
Vodicka Josef,
Mukensnabl Petr,
Vejvodova Sarka,
Spidlen Vladimir,
Kulda Vlastimil,
Topolcan Ondrej,
Pesta Martin
Publication year - 2018
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.24826
Subject(s) - medicine , lymph , histopathological examination , immunohistochemistry , staining , haematoxylin , nuclear medicine , eosin , h&e stain , pathology , surgery
Background Detection of tumor cells in lymph nodes (LNs) removed during the treatment of pulmonary tumor by radical surgery is limited by the possibilities of standard histopathological methods. The goal of this study was to obtain more accurate pTNM status by a more sensitive detection of micrometastases in LNs. Methods A total of 885 LNs, an average of 13.8 LNs per patient, were removed during 64 surgeries. LNs from the same zone were pooled together as a group, five groups of LNs were examined in each patient. A total of 320 groups of LNs were examined. One‐step nucleic acid amplification (OSNA) method was compared to standard histopathological examination with haematoxylin‐eosin (H&E) staining and CK19 immunohistochemistry, specifically by an ultimate analysis of all intraoperatively removed LNs. Results Identical results for H&E and OSNA examinations were recorded in 286 groups of LNs (89.4%). In total, positive examinations were recorded in 27 groups of LNs (8.4%) using the OSNA method, which were H&E negative. In seven groups of LNs (2.2%), the H&E examination was positive, while OSNA method produced negative results. Conclusions The OSNA examination led to a higher pTNM stage classification in 14 (21.9%) patients. The clinical significance remains the subject of follow‐up research.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here